Mass General Hospital

Harvard Medical School

Goodbye 2016: The Year in Review

Happy New Year!

It is that time of the year again when we take the time to look back and review the previous year.  Probably the most striking thing I see is the sheer volume of articles published in the field of reproductive psychiatry.  

This means that it has been a great year for our website as well, with over 1.2 million visits.  Thanks to all of our readers!

Ruta Nonacs, MD PhD

 

Looking at the stats, these were the most popular posts on our site in 2016:

You Asked:  Is It Safe to Take Melatonin During Pregnancy?

Smoking While Breastfeeding: What Are the Risks?

How to Treat Anxiety Symptoms During Pregnancy

Clinical Update: Use of Stimulant Medications in Pregnancy

Treatment of Insomnia During Pregnancy

Does Depo-Provera Cause Mood Changes?

Zolpidem (Ambien) in Pregnancy: Is it Safe?

Teen PMS and PMDD Guide

You Asked: Is Duloxetine (Cymbalta) Safe To Use During Pregnancy?

Breastfeeding and Benzodiazepines: Good News

 

I would also like to take this opportunity to highlight some of the most important issues in 2016:

We continue to move forward with screening for depression in all pregnant and postpartum women; however, we continue to struggle in terms of ensuring that we can  provide consistent access to specialized care for women with perinatal mood and anxiety disorders.

Panel Recommends Depression Screening For Pregnant And Postpartum Women

Perinatal Depression Screening: New Recommendations and Challenges

Will Insurers Make it More Difficult to Screen for Depression  in Pregnancy and Postpartum Women?

 

Many studies have explored novel strategies in order to reach and provide care to women with perinatal mood and anxiety disorders:

MCPAP for Moms: Exploring New Strategies for Providing Care to Women with Perinatal Depression

Therapist-Assisted, Internet-Delivered CBT for Depression in Postpartum Women

 

Atypical antipsychotic medications are now commonly used to treat a spectrum of psychiatric disorders.  We are finally getting more data on the reproductive safety of these medications, and the data has been reassuring.  

New Research from the CWMH: Evaluating the Risk of Major Malformations in Children Prenatally Exposed to Atypical Antipsychotics

New Research from the CWMH: Prenatal Exposure to Atypical Antipsychotics Does Not Increase Risk of Malformations

National Pregnancy Registry for Atypical Antipsychotics

 

When we discuss the treatment of depression during pregnancy, we must weigh the possible risks associated with medication exposure against the risk of untreated depression in the mother.  We continue to see more studies documenting the negative effects of maternal depression on pregnancy and the developing fetus.

New Studies: How Maternal Depression Affects the Developing Brain

 

And there has been at least one study indicating that treatment with medication may actually decrease the risk of adverse outcomes in women with depression during pregnancy:

Pilot Study: Treatment of Antenatal Depression Associated with Improved Infant Outcomes

 

More states have legalized marijuana.  We are seeing more and more women using marijuana on a regular basis who are either pregnant and planning to conceive, despite limited information regarding the reproductive safety of this drug.

Use of Marijuana on the Rise in Pregnant Women

Cannabis and Pregnancy: Increasing Use, Still Not Enough Data on Safety

Prenatal Cannabis Exposure May Affect Fetal Brain Development

 

We have heard about the opioid epidemic in the United States.  The problem has now trickled down to infants and children.  

The US Opioid Epidemic:  More US Infants Born With Drug Dependence

 

Share This Page:
Email this to someoneShare on Facebook0Tweet about this on TwitterShare on Google+0Share on LinkedIn3Share on Reddit0Buffer this pagePrint this page

, , , , , , , , , , ,

No comments yet.

Leave a Reply